NCT01115803 2019-02-05
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
Eli Lilly and Company
University of California, Davis
University of Chicago
Emory University
Vanderbilt-Ingram Cancer Center